Rewriting the Biology of Autoimmune Disease
Candid Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for autoimmune and inflammatory diseases. Founded in 2023 and backed by $370M in funding, the company is building a pipeline of next-generation immunology treatments targeting unmet medical needs in conditions such as lupus and myasthenia gravis.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2026
Sep 2024
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
